Viatris Inc. operates as a global pharmaceutical and healthcare corporation, a behemoth forged in 2020 from the strategic combination of Mylan and Pfizer's Upjohn business. Its core mission revolves around providing access to a vast array of medicines, essentially ensuring that once a drug's intellectual property expires, a cost-effective alternative is readily available. The company’s portfolio is a veritable pharmacopeia, boasting over 1,400 approved therapeutic molecules, encompassing established branded generics, traditional generics, complex generics, biosimilars, and even a selection of over-the-counter products. These offerings span critical therapeutic areas including cardiovascular, infectious disease, oncology, and immunology, among others.

Operating within the "Drug Manufacturers - Specialty & Generic" sector, Viatris employs a business model that leverages its immense global commercial reach, formidable manufacturing capabilities, and regulatory prowess to distribute its products across more than 165 countries and territories. Headquartered in Canonsburg, Pennsylvania, its operational footprint includes major global centers in Shanghai and Hyderabad, alongside approximately 40 manufacturing sites worldwide. This expansive infrastructure provides a significant competitive advantage, enabling scale and a robust supply chain crucial for delivering essential medicines globally.

The company's very existence is a testament to the pursuit of widespread pharmaceutical availability, a global journey to dominate the post-patent landscape. This isn't just about selling pills; it's about strategically navigating regulatory mazes and supply chain complexities to ensure that, ideally, no corner of the world is left without a cost-effective alternative to a blockbuster drug. A noble pursuit, some might say, especially when considering the alternative of exorbitant brand-name pricing, though the path to universal access is, predictably, paved with regulatory hurdles and the occasional class-action lawsuit. Indeed, Viatris has faced its share of scrutiny, from historic debates surrounding Mylan's EpiPen pricing to more recent FDA warning letters concerning manufacturing quality and data integrity at its Indian facilities, leading to divestitures and a strategic pivot towards higher-value assets. It’s the pharmaceutical equivalent of a global scavenger hunt for expiring patents, ensuring that once a drug's intellectual property expires, Viatris is there, ready to replicate and distribute, often at a fraction of the original cost – a true hero for healthcare budgets, if not always for brand loyalty.